Dr. Howard Verrico reports

SIRONA BIOCHEM INITIATES COVID-19 AND INFECTIOUS DISEASES DEVELOPMENT PROGRAM

Sirona Biochem Corp.'s French subsidiary lab, TFChem, has initiated an anti-viral program to produce potential new anti-viral agents to assist in combatting COVID-19 and other infectious diseases.

After two months of extensive research, TFChem scientists have determined the proprietary platform technology can be applied to develop new anti-viral compounds. Work on this program has begun with a goal to produce new therapies in three current anti-viral categories: neuraminidase inhibitors, nucleoside analogues and iminosugars. These categories are all glycosides with a carbohydrate core and therefore suitable for application of the technology. The goal is to develop novel multitarget anti-viral compounds, affecting different steps of the viral life cycle. The company believes there is a high therapeutic potential for these glycosides.

Viruses are a leading cause of death globally. Therapies to treat most viral infections are limited and the emergence of new viruses can greatly endanger society, as is currently the case with the pandemic caused by COVID-19, also known as coronavirus or SARS-CoV-2. There is a need to identify novel, effective and safe drugs to treat viral infections. Awareness of the value of this project and other anti-viral projects continuing globally has become apparent.

"We have the financial resources to initiate this project and anticipate we will secure further non-dilutive financing to support the project ongoing. We are working to secure new senior laboratory technicians to join our current team at TFChem and have identified suitable candidates within France that will greatly expand our capabilities. We will also reach out to our current partners to explore how their capabilities can assist us in this project. None of these efforts will affect our current core projects which are principally managed by different team members than are involved in early-stage compound synthesis," said Dr. Howard Verrico, chief executive officer of Sirona Biochem.

"These are difficult times with our global battle against COVID-19. We are receiving tremendous support from the French government and have a dedicated team who are always searching for new opportunities to apply our technology. Dr. Geraldine Deliencourt-Godefroy, our chief scientific officer, has a proven ability to identify projects with significant probabilities of clinical success. On her recommendation and the recognition to potentially deliver novel therapies that can benefit the global population, we have decided to proceed with this program," Dr. Verrico added.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona's subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

We seek Safe Harbor.